跳至主要内容
临床试验/EUCTR2007-000634-39-DE
EUCTR2007-000634-39-DE进行中(未招募)不适用

Postpartum Intervention in Women with Gestational Diabetes using Insulin - PINGUI

Forschergruppe Diabetes e. V. am Helmholtz Zentrum München0 个研究点开始时间: 2009年3月27日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • 1.Female subjects who are at least 18 years of age, who are less than 7
  • months post-partum, and who had insulin treated GDM during their most
  • recent pregnancy (see 8)
  • 2.Written informed consent to participate in the study
  • 3.Ability to comply with all study requirements
  • 4.Agree with the medication after finishing with breast feeding
  • 5.Contraception after the last pregnancy for the next 2 years
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1.Pregnant or lactating female
  • 2.GAD antibody or IA-2 antibody positive
  • 3.Diabetes, defined as any of the following (FPG > 126mg/dL (7.0 mmol/L) at visit 1 or 2-hr post-challenge plasma glucose (after a 75-g OGTT) > 200 mg/dL (11.1 mmol/L) or diabetes diagnosed by a physician and confirmed by other clinical data, other than gestational diabetes
  • 4.Use of insulin or any oral antidiabetic agents after pregnancy and prior to visit 1
  • 5.concomitant use of drugs that affect carbohydrate metabolism
  • 6.psychiatric disorders
  • 7.history of vein thrombosis
  • 8.bleeding disorders by clinical history
  • 9.severe maternal or fetal complications during pregnancy
  • 10.dietary only treatment during pregnancy
  • 11.family planning within the next two years
  • 12.Any of the following ECG abnormalities: Torsades de pointes, sustained and clinically relevant ventricular tachycardia or ventricular fibrillation, second degree AV block (Mobitz 1 and 2), third degree AV block, prolonged QTc (> 500 ms)
  • 13.malignancy including leukemia and lymphoma within the last 5 years
  • 14.liver disease such as cirrhosis or chronic active hepatitis
  • 15.treatment with growth hormone or similar drugs
  • 16.chronic oral or parenteral corticosteroid treatment (> 7 consecutive days of treatment) within 8 weeks prior to visit 1
  • 17.treatment with class Ia, Ib and Ic or III anti-arrhythmics
  • 18.any significant laboratory abnormalities at visit 1
  • 19. Any of the following significant laboratory abnormalities
  • ALT, AST > 2 times the upper limit of the normal range (ULN) at visit 1, confirmed by a repeat measure within 3 working days
  • Total bilirubin > 2 times ULN and direct bilirubin > ULN at visit 1, confirmed by a repeat measure within 3 working days
  • 20. Participation in another clinical trial within the last 3 months
  • 21. Blood loss (e.g. by blood donation) of > 400 ml within the last 2 months
  • 22. Any disease or condition which could impair study participation in the opinion of the
  • investigator

研究者

发起方
Forschergruppe Diabetes e. V. am Helmholtz Zentrum München

相似试验